Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012, with the announcement issued on June 8, 2012. The filing details an extension of GSK's tender offer to acquire all outstanding shares of Human Genome Sciences (HGS).
Key Financial Metrics and Transaction Details
- Offer Price: US$13.00 per share in cash.
- Premium: 81% premium over HGS's closing share price of US$7.17 on April 18, 2012.
- Expected Synergies: At least US$200 million in cost synergies.
- Shares Tendered: Approximately 474,029 shares (including 24,856 shares subject to guarantees of delivery) as of June 7, 2012, midnight New York City time.
- Financial Performance: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for GSK or HGS.
Material Changes and Transaction Status
The primary material change is the extension of the tender offer expiration date from midnight on June 7, 2012, to 5:00 p.m. New York City time on June 29, 2012. All other terms and conditions of the offer remain unchanged from the amended tender offer documents filed on May 10 and May 23, 2012.
Guidance, Outlook, and Risks
Management Commentary: GSK management asserts the offer represents full and fair value, aligning with a long-term strategy to deliver sustainable growth, simplify the business model, enhance R&D returns, and deploy capital with discipline. The offer targets the value of HGS assets including Benlysta, darapladib, and albiglutide.
Risks and Contingencies: The closing is subject to terms and conditions in the Schedule TO filings. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific risk factors are referenced in GSK's 2011 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the total number of shares tendered and accepted as of the new expiration date (June 29, 2012).
- Confirm the final closing conditions and regulatory approvals required for the acquisition.
- Review the detailed Schedule TO filings (May 10 and May 23, 2012) for specific terms and conditions.
- Assess the integration plan and realization timeline for the projected US$200 million in cost synergies.
- Monitor the status of HGS's key assets (Benlysta, darapladib, albiglutide) post-acquisition.